U.S. secures 300 million doses, almost a third, of potential AstraZeneca COVID-19 vaccine

[PeteS in CA]

https://business.financialpost.com/technology/u-s-secures-300-million-doses-of-potential-astrazeneca-covid-19-vaccine-3

U.S. secures 300 million doses, almost a third, of potential AstraZeneca COVID-19 vaccine
Reuters, Aakash B and Guy Faulconbridge and Kate Holton
May 21, 2020, 8:53 AM EDT, Last Updated May 21, 2020, 12:31 PM EDT

The United States has secured almost a third of the first one billion doses planned for AstraZeneca’s experimental COVID-19 vaccine by pledging up to $1.2 billion, as world powers scramble for medicines to get their economies back to work.

While not proven to be effective against the coronavirus, vaccines are seen by world leaders as the only real way to restart their stalled economies, and even to get an edge over global competitors.

After President Donald Trump demanded a vaccine, the U.S. Department of Health agreed to provide up to US$1.2 billion to accelerate AstraZeneca’s vaccine development and secure 300 million doses for the United States.
...
The vaccine, previously known as ChAdOx1 nCoV-19 and now as AZD1222, was developed by the University of Oxford and licensed to British drugmaker AstraZeneca. ...

[Free Vulcan]

Voluntary I hope.

[aligncare]

I plan on being part of the 30 million.

[PeteS in CA]

https://hotair.com/archives/john-s-2/2020/05/22/oxford-vaccine-moves-phase-ii-human-trials/

Oxford Vaccine Moves To Phase II Of Human Trials
JOHN SEXTON, Posted at 2:41 pm on May 22, 2020

A coronavirus vaccine produced by researchers at Oxford University started Phase 1 trials involving around 1,000 people last month. Today, those trials advanced to the next stage of human trials involving many more volunteers.

An experimental vaccine for COVID-19 under development at Oxford University hit a milestone Friday with researchers announcing it will be progressing to advanced stages of human trials.

It will be tested in 10,260 volunteers across the United Kingdom to determine how effective it is at preventing infection, the university said in a statement. If successful, it could be on the market as early as September, according to British-Swedish drugmaker AstraZeneca, which partnered with the university in April to manufacture and distribute the vaccine…